Li Basuino1, Ambre Jousselin2, J Andrew N Alexander3, Natalie C J Strynadka3, Mariana G Pinho2, Henry F Chambers1, Som S Chatterjee1. 1. Division of HIV/AIDS, Infectious Diseases and Global Health, Department of Medicine, University of California, San Francisco, CA, USA. 2. Instituto de Tecnologia Química e Biológica António Xavier, Universidade Nova de Lisboa, Oeiras, Portugal. 3. Department of Biochemistry and Molecular Biology and the Center for Blood Research, University of British Columbia, Vancouver, British Columbia, Canada.
Abstract
Background: PBP4 is typically considered unimportant for conferring high-level β-lactam resistance in Staphylococcus aureus. Mutations in PBP4 have been associated with β-lactam non-susceptibility among natural strains of S. aureus. We have previously shown that PBP4 can mediate high-level β-lactam resistance in laboratory-generated strains passaged in β-lactam antibiotics. Mutations in the pbp4 promoter that up-regulate its expression and missense mutations that surround PBP4's active site were detected in high frequencies among passaged strains, suggesting PBP4 plays a key role in resistance. How these mutations participate in PBP4's ability to provide high-level β-lactam resistance is unknown. Objectives: To determine whether enzymatic activity of PBP4 is required for high-level β-lactam resistance and to investigate how the pbp4-associated mutations provide β-lactam resistance. Methods: The catalytic activity of PBP4 was disabled through introduction of a serine to alanine point mutation in its active site (Ser-75→Ala) in a representative and well-studied passaged strain, CRB. pbp4 promoter and missense mutations detected in CRB were reconstituted in a WT strain individually and in combination. β-Lactam resistance of the resultant strains was evaluated by population analysis. Bacterial peptidoglycan composition of the pbp4 mutants was evaluated with and without antibiotic treatment using LC. Results: PBP4 inactivation imparted complete β-lactam susceptibility of CRB. Reconstitution of PBP4 missense mutations alone did not impart β-lactam resistance, but did so in synergism with pbp4 promoter mutation. A similar synergistic interaction of pbp4 mutations was observed in enhanced peptidoglycan cross-linking upon antibiotic treatment. Conclusions: PBP4's activity and overexpression both contribute to high-level β-lactam resistance.
Background: PBP4 is typically considered unimportant for conferring high-level β-lactam resistance in Staphylococcus aureus. Mutations in PBP4 have been associated with β-lactam non-susceptibility among natural strains of S. aureus. We have previously shown that PBP4 can mediate high-level β-lactam resistance in laboratory-generated strains passaged in β-lactam antibiotics. Mutations in the pbp4 promoter that up-regulate its expression and missense mutations that surround PBP4's active site were detected in high frequencies among passaged strains, suggesting PBP4 plays a key role in resistance. How these mutations participate in PBP4's ability to provide high-level β-lactam resistance is unknown. Objectives: To determine whether enzymatic activity of PBP4 is required for high-level β-lactam resistance and to investigate how the pbp4-associated mutations provide β-lactam resistance. Methods: The catalytic activity of PBP4 was disabled through introduction of a serine to alanine point mutation in its active site (Ser-75→Ala) in a representative and well-studied passaged strain, CRB. pbp4 promoter and missense mutations detected in CRB were reconstituted in a WT strain individually and in combination. β-Lactam resistance of the resultant strains was evaluated by population analysis. Bacterial peptidoglycan composition of the pbp4 mutants was evaluated with and without antibiotic treatment using LC. Results:PBP4 inactivation imparted complete β-lactam susceptibility of CRB. Reconstitution of PBP4 missense mutations alone did not impart β-lactam resistance, but did so in synergism with pbp4 promoter mutation. A similar synergistic interaction of pbp4 mutations was observed in enhanced peptidoglycan cross-linking upon antibiotic treatment. Conclusions: PBP4's activity and overexpression both contribute to high-level β-lactam resistance.
Authors: M Angeles Argudín; M Dodémont; M Taguemount; S Roisin; R de Mendonça; A Deplano; C Nonhoff; O Denis Journal: J Antimicrob Chemother Date: 2016-09-15 Impact factor: 5.790
Authors: Stephanie M Hamilton; J Andrew N Alexander; Eun Ju Choo; Li Basuino; Thaina M da Costa; Anatoly Severin; Marilyn Chung; Sandra Aedo; Natalie C J Strynadka; Alexander Tomasz; Som S Chatterjee; Henry F Chambers Journal: Antimicrob Agents Chemother Date: 2017-05-24 Impact factor: 5.191
Authors: Ritu Banerjee; Michael Gretes; Christopher Harlem; Li Basuino; Henry F Chambers Journal: Antimicrob Agents Chemother Date: 2010-08-30 Impact factor: 5.191
Authors: Liana C Chan; Aubre Gilbert; Li Basuino; Thaina M da Costa; Stephanie M Hamilton; Katia R Dos Santos; Henry F Chambers; Som S Chatterjee Journal: Antimicrob Agents Chemother Date: 2016-06-20 Impact factor: 5.191
Authors: Douglas J Biedenbach; Richard A Alm; Sushmita D Lahiri; Edina Reiszner; Daryl J Hoban; Daniel F Sahm; Samuel K Bouchillon; Jane E Ambler Journal: Antimicrob Agents Chemother Date: 2015-10-26 Impact factor: 5.191
Authors: Alexander L Greninger; Som S Chatterjee; Liana C Chan; Stephanie M Hamilton; Henry F Chambers; Charles Y Chiu Journal: PLoS One Date: 2016-02-18 Impact factor: 3.240
Authors: J Andrew N Alexander; Mariia Radaeva; Dustin T King; Henry F Chambers; Artem Cherkasov; Som S Chatterjee; Natalie C J Strynadka Journal: J Biol Chem Date: 2020-06-09 Impact factor: 5.157
Authors: J Andrew N Alexander; Som S Chatterjee; Stephanie M Hamilton; Lindsay D Eltis; Henry F Chambers; Natalie C J Strynadka Journal: J Biol Chem Date: 2018-10-26 Impact factor: 5.157
Authors: Stefano G Giulieri; Romain Guérillot; Sebastian Duchene; Abderrahman Hachani; Diane Daniel; Torsten Seemann; Joshua S Davis; Steven Y C Tong; Bernadette C Young; Daniel J Wilson; Timothy P Stinear; Benjamin P Howden Journal: Elife Date: 2022-06-14 Impact factor: 8.713